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1. Introduction 
Hepatitis C virus (HCV) is a unique virus whose life cycle is closely associated with 
lipoprotein metabolism [1, 2, 3]. Assembly of HCV particles, formation of HCV-virions, is 
closely connected to the formation of lipid droplets in hepatic cells that may serve as an 
assembly platform [1, 4]. In addition, the production of HCV particles is tightly linked to the 
very low-density lipoprotein (VLDL) production pathway [5, 6]. HCV particles circulating 
in the blood during chronic HCV infection form lipo-viral particles (LVP) that are rich in 
triglycerides (TG), apoB-100 and apoE, with physiochemical similarity to VLDL particles 
and are highly infectious [7, 8]. In contrast, denser HCV particles are less infectious. These 
data strongly suggest that both viral particles and VLDL are integral components of LVPs 
with high infective capability. Although LVPs are thought to be assembled in liver cells by 
association with host lipoproteins prior to secretion, association between HCV and VLDL in 
the circulation after secretion from the liver cannot be ruled out. 
Studies to date have indicated that the process of HCV assembly and secretion largely 
utilizes the VLDL pathway. Therefore, suppression of apoB-100 or apoE also inhibits 
secretion of HCV. Inhibition of microsomal triglyceride transfer protein (MTP), a critical 
protein for the initial step of VLDL assembly by co-translational lipidation of apoB-100 [9, 
10], inhibits HCV secretion.  
As HCV depends on VLDL pathways for its assembly and secretion, the lipid-rich 
environment of the liver cell combined with reduced VLDL secretion may be required for 
efficient assembly and secretion of HCV virions by ensuring the feasibility of co-assembly 
with VLDL. Hypobetalipoproteinemia, reduced activity of MTP with negative correlation to 
hepatic steatosis and viral load, is observed in HCV-G3 chronic infection [11]. Secretion of 
apoB-100 was reduced by HCV nonstructural proteins using the HCV subgenomic replicon 
expression system and interaction between the HCV NS5A and apoB-100 was observed [12]. 
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In addition, there has been accumulating evidence that the HCV core protein is induced 
upon the redistribution of lipid droplets, affecting the assembly of both HCV and VLDL [13, 
14]. The function of core protein in lipid metabolism has been widely examined including in 
models of steatosis involving HCV core protein transgenic mice [15]. Findings include 
reduction in activity of MTP [9] and Tyr164Phe substitution in relation to marked steatosis 
in HCV-G3 infection [16]. Although the participation of Arg70Gln/His substitution in 
steatosis of hepatocytes has been proposed [17], the precise connection between hepatic 
steatosis and HCV-G1b and/or HCV-G2 infection remains unclear. 
As mentioned earlier, HCV particles in peripheral blood may associate not only with VLDL, but 
also with other lipoproteins, especially LDL, since circulating LVPs span a wide range of 
buoyant gravity and physicochemical characteristics [8, 18]. The association of lipoproteins with 
HCV particles may be beneficial for HCV through protection against anti-HCV neutralizing 
antibodies, as the antigenicity of HCV surface proteins is hidden beneath the associated 
lipoprotein particle [18]. Lipoprotein particles isolated from sera of HCV patients displayed 
differentially modulated lipid synthesis in human monocyte-derived macrophages in 
comparison to lipoproteins obtained from normal subjects, suggesting that HCV infection 
influences the biochemical composition of lipoproteins, thus revealing an alternative influence 
on lipid metabolism [19]. HCV entry into liver cells may occur through many receptors, 
including CD81 (direct binding to HCV E2 protein) and claudin-1, both of which act during the 
later steps of HCV entry [20]. The predominant role of LDL-receptors or remnant receptors is to 
catch VLDL-derived lipoprotein particles. Meanwhile, SR-BI (a receptor for HDL and oxidized 
LDL) directly binds HCV E2 protein [21]. Very recently, Nieman-Pick C1-like 1 cholesterol 
absorption receptor has been reported as a new factor for HCV entry to hepatic cells [22]. 
Interestingly, lipoprotein lipase, which hydrolyzes VLDL, is reported to increase the binding of 
LVP to hepatic cells while simultaneously decreasing infection levels of hepatic cells [23].  
These findings suggest that examination of serum lipid profiles in chronic HCV infection 
may be important for understanding the biological features of HCV infection. Compared to 
normal subjects, low levels of TC, high-density lipoprotein cholesterol (HDL-C) and LDL-C 
was reported in chronic HCV-G3a infection [24]. However, lipoprotein profiles in infections 
of genotypes other than HCV-G3 have not been fully described and the data are somewhat 
conflicted. Moriya et al. indicated that TC levels and apoB, CII and CIII were reduced in 
HCV-G1b compared with chronic HCV-G2a or hepatitis B virus (HBV) infection [25], while 
others have not reported such a distinction. In addition, distortion of serum lipid levels has 
been widely observed in connection with virological outcome of IFN-based antiviral 
therapy, especially in HCV-G1 infection. Lower LDL-C, HDL-C, TC and/or TG was reported 
to be a possible predictor for unfavorable response to IFN-based therapy [24, 26, 27]. 
However, after the discovery of a genetic polymorphism near the human IL28B gene as the 
most potent predictor of the outcome of IFN-based therapy, the distortion of serum lipid 
levels is no longer thought to be an independent factor, but rather a confounding variable 
for predicting therapeutic efficacy [28]. 
In this chapter, we described the lipoprotein profiles in chronic HCV-G1b infection (the 
most common genotype in Japan) compared with that in chronic HCV-G2 infection (the 
second most common genotype in Japan). In addition, the influence of the genetic 
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polymorphism near the human IL28B gene and aa substitutions in the core and NS5A 
regions of HCV on lipoprotein profiles in chronic HCV-G1b infection was determined. 
To examine the serum lipid profiles of many patients, ultracentrifugation was unsuitable. 
We instead measured serum lipoprotein using HPLC in addition to a conventional 
laboratory method involving measurement of apolipoproteins. To examine serum LDL-C 
levels, the Friedwald equation can be used as an indirect calculation method yielding “total 
cholesterol minus HDL-C minus 0.2  TG. However, the precision of this equation has not 
been determined in pathological conditions such as chronic HCV infection.  
2. Methods 
2.1. Patients and materials 
Fasting sera of patients who were diagnosed as having chronic HCV infection were 
collected and stored at lower than -30 degrees centigrade until examination of 
apolipoproteins and/or lipoproteins. At the time of serum collection, TC, TG and HDL-C 
were measured using a routine laboratory kit. Serum LDL-C was measured by a direct assay 
using an LDL-cholesterol kit (Sekisui Medical, Japan). A good correlation between the direct 
assay and indirect measurement using the Friedwald equation (r=0.96) in 96 healthy adults 
whose TG level was lower than 400 mg/dl was observed. 
Detection of HCV infection was made using a commercial real-time PCR Kit. Detection of 
HCV genotype was performed by a PCR method based on the 5’ non-coding sequence. 
Some patients diagnosed as having HCV-G1b infection, aa substitutions at core 70/91, 
interferon sensitivity determined region (ISDR) and/or IFN RBV resistance determining 
region (IRRDR) were examined. All patients examined were Japanese without ongoing 
treatment of IFN-based antiviral therapy. 
All patients were confirmed not to be co-infected with HIV, HTLV, tuberculosis or other 
chronic bacterial infections. In addition, patients who were diagnosed with hepatic cirrhosis 
were excluded from the study. Study protocols were approved by the review board of each 
institution and written informed consent was obtained prior to study enrollment. 
2.2. Detection of serum apolipoproteins 
Serum levels of apolipoproteins (apoA1, apoA11, apoB, apoCII, apoCIII and apoE) were 
analyzed by immunonephelometry using an apolipoprotein detection kit (Sekisui Medical, 
Japan). Serum apoB-48 was assayed by chemiluminescent enzyme immunoassay [29] using 
an apoB-48 CLEIA kit (Fujirebio, Japan). Serum apoB-100 level was determined as apoB 
minus apoB-48. 
2.3. Detection of lipoprotein fractions by HPLC based method 
Fasting serum lipoprotein profiles were analyzed using an HPLC system with on-line 
enzymatic dual detection of cholesterol and TG as described previously (LipoSEARCH, 
Skylight Biotech, Japan) [30]. Briefly, 10 l of whole serum sample was injected into two 
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connected columns (300  7.8 mm) of TSKgel LipopropakXL (Tosoh, Japan) and eluted by 
TSKeluent Lp-1 (Tosoh). The eluent from the columns was divided by a micro splitter and 
continuously monitored at 550 nm after an online enzymatic reaction with a commercial kit, 
Determiner L TC (Kyowa Medex, Japan) and Determiner L TG (Kyowa Medex). Then, the 
cholesterol and TG concentrations were calculated by the computer program, which was 
designed to process complex chromatograms with a modified Gaussian curve fitting for 
resolving overlapping peaks by mathematical treatment. 
Lipoprotein particles were fractionated into four major lipoproteins according to particle 
diameter as follows: >80 nm classified as chylomicrons; 30 to 80 nm as VLDL; 16 to 30 nm as 
LDL; and 8 to 16 nm as HDL. Next, the concentration of cholesterol and TG was measured 
in each major lipoprotein fraction and the ratio of cholesterol:TG concentration (C:T ratio) 
was calculated. This system has been successfully applied elsewhere in clinical research 
with excellent reproducibility [31]. Although freezing and thawing may affect the 
lipoprotein fraction, the influence of freezing and thawing on the measurement of 
cholesterol and TG concentration in healthy samples is fairly low, as described on homepage 
of Skylight Biotech (http://www.lipo-search.com). 
Figure 1 illustrates chromatographic pattern of cholesterol and triglycerides derived 
LipoSEARCH was illustrated.  
 
Figure 1. Chromatographic pattern of fasting serum cholesterol and TG derived HPLC-based method 
(LipoSEARCH). 
2.4. Detection of amino acid substitutions at aa 70/91 in core region of HCV-G1b 
HCV RNA was extracted from serum samples and reverse transcribed with random primers 
and MMLV reverse transcriptase (Takara Shuzo, Japan). Based on the method of Akuta et al. 
[32], nucleotide sequences of the core region were analyzed by direct sequencing after nested 
PCR. Subsequently, the aa substitutions at position 70 (arginine, Arg70; or glutamine/histidine, 
Gln70/His70) and at position 91 (leucine, Leu91; or methionine Met91) were determined. 
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2.5. Detection of amino acid substitutions related to ISDR in NS5A of HCV-G1b  
Nucleotide sequences of NS5A-ISDR were analyzed by direct sequencing after double-
round PCR according to Enomoto et al. [33]. Then, the aa sequence from 2209-2248, termed 
the ISDR region, in NS5A was determined and the numbers of aa substitutions defined. 
2.6. Detection of amino acid substitutions related to IRRDR in NS5A of HCV-
G1b  
Nucleotide sequences of NS5A-IRRDR were analyzed by direct sequencing after double-
round PCR according to El-Shamy et al. [34] and the numbers of aa substitutions within this 
region (2334-2376) determined. Moreover, the particular position of aa substitutions were 
evaluated in connection to dyslipoproteinemia, found in chronic HCV-G1b patients. 
3. Results 
Difference in lipoprotein profiles between patients with chronic HCV-G2 and HCV-G1b 
infection, between HCV-G1b patients with favorable and unfavorable response to PEG-IFN 
plus RBV combination therapy, and between minor (non-responder) genotypes and major 
(responder) genotypes of IL28B (rs8099917) 
Serum lipoprotein profiles are clearly distorted in patients with chronic HCV-G3 infection 
and this is characterized by a decrease in apoB-100-related cholesterol [24]. However, serum 
lipoprotein disturbances in other genotypes are an issue that has been under discussion. In 
addition, disturbances in lipoprotein profiles have been reported in patients who were not 
responsive to IFN-based antiviral therapy in comparison to responsive patients with chronic 
HCV-G1 infection [26, 27]. However, whether or not dyslipoproteinemia is an independent 
factor affecting the efficacy of IFN-based therapy remains controversial. The latest 
interpretation seems to be that dyslipoproteinemia in HCV-G1 patients may be a 
confounding factor of the host genotype of IL28B that is the strongest predictor for 
virological outcome following PEG-IFN plus RBV therapy [28]. 
Initially, we compared serum levels of apolipoproteins in chronically HCV-G2- and G1b-
infected patients paying special attention to virological outcome of PEG-IFN plus RBV 
therapy in the HCV-G1b patients. Of the pre-treatment fasting sera taken from 42 HCV-G1b 
patients, 23 achieved a sustained viral response (SVR; negative for HCV RNA at 6 months 
after standard 48 weeks of therapy); 8 had a transient viral response (TVR; HCV RNA-
negative during therapy, but reappearing after therapy); and 11 had a non-viral response 
(NVR; HCV RNA-positive during therapy). 24 HCV-G2 patients were also examined. 
There were no differences in the concentration of apoAI, apoAII, apoCIII, apoE and apoB-48 
(138.2±27.4 mg/dl vs. 142.4±32.4 mg/dl, 30.4±6.5 mg/dl vs. 29.9±4.8 mg/dl, 5.7±2.0 mg/dl vs. 
6.2±2.4 mg/dl, 4.4±1.1 mg/dl vs. 4.3±1.0 mg/dl and 3.3±4.2 mg/dl vs. 3.1±1.4 mg/dl, respectively) 
between HCV-G1b and G2 patients. In addition, no significant changes were observed among 
patients with HCV-G1b showing different outcome of PEG-IFN plus RBV therapy. However, 
there were substantial differences in apoB and apoCII levels according to the response to PEG-
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IFN plus RBV therapy in HCV-G1b patients. In HCV-G1b infection, apoB and apoCII levels 
were significantly higher in SVR patients than in NVR patients. The levels of apoB and apoCII 
in HCV-G2 patients were similar to those in HCV-G1b patients who achieved SVR (Figure 2). 
These data suggest that the apolipoprotein profile in HCV-G1b patients is basically 
indistinguishable from that in HCV-G2 patients. Meanwhile, the profile differed in relation 
to different outcomes of PEG-IFN plus RBV therapy among chronic HCV-G1b infection. 
From these observations, we presumed that a decrease in LDL and/or VLDL may be a 
feature of dyslipoproteinemia in HCV-G1b patients who failed to respond to PEG-IFN plus 
RBV therapy. ApoB-100 (about 95% of apoB is apoB-100 in fasting sera) is an indicator of 
total VLDL, intermediate-density lipoprotein (IDL) and LDL particles in the blood because 
each particle of VLDL, IDL or LDL is composed of one molecule of apoB-100. Moreover, the 
majority of apoCII, which activates the enzyme lipoprotein lipase in capillaries, is associated 
with VLDL. Therefore, a decrease in apoCII could be related to a decrease in VLDL. Taking 
into consideration these observations, we concluded that a characteristic of the lipoprotein 
profile during the pre-treatment period of chronic HCV-G1b patients who subsequently fail 
antiviral IFN-based therapy is a decline in VLDL levels. Although lower serum apoE has 
recently been reported to be related to a favorable response to IFN-based therapy [35], we 
did not find any differences in serum apoE levels. 
 
Figure 2. Serum apoB and apoCII levels in patients with chronic HCV-G1b or HCV-G2 infection. All 
HCV-G1b patients were treated with standard PEG-IFN plus RBV combination therapy and clarified 
according to the virological response. (NVR; non-viral response, TVR; transient viral response, SVR; 
sustained viral response) 
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Next, we examined the profiles of serum lipoproteins in 32 patients who were chronically 
infected with HCV-G2 and 111 patients with HCV-G1b, along with genotyping of the region 
near the IL28B gene (SNP ID rs8099917), the strongest predictor of outcome to PEG-IFN plus 
RBV therapy. Recently, we reported that serum apoB-100 levels are prescribed by genetic 
polymorphism of rs8099917, and a minor genotype of rs8099917 (TG or GG; also known as 
non-responder genotype of PEG-IFN plus RBV combination therapy) may be related to a 
decrease in serum apoB-100 in chronic HCV-G1b infection [36]. In chronic HCV-G1b 
infections in Japan, the minor genotype was found in 25-35% of cases, whereas it was only 
10-20% in chronic HCV-G2 infections. We examined SNP of rs8099917 and the lipoprotein 
profiles obtained by LipoSEARCH were compared among 29 HCV-G2 patients who had the 
major genotype of IL28B (rs8099917), 75 HCV-G1b patients who had the major IL28B 
genotype and 36 HCV-G1b patients who had the minor IL28B genotype. 
There were no differences related to gender, age, fibrosis score of liver biopsy, BMI, serum 
ALT level, viral load or platelet count among these three groups (data not shown). We did 
not cite the chylomicron fraction because this fraction was too small to analyze precisely. 
 
Lipoprotein fraction TC VLDL-C LDL-C HDL-C 
HCV-G2, IL28B major   167.92±31.20 38.22±17.65 81.18±22.25 44.79±14.49 
HCV-G1b, IL28B major 169.65±30.52 45.52±18.64 72.80±17.27* 46.54±12.22 
HCV-G1b, IL28B minor 161.69±30.87 36.22±15.18*** 68.61±18.40* 52.20±16.64** 
(mg/dl) 
Lipoprotein fraction TG VLDL-TG LDL-TG HDL-TG 
HCV-G2, IL28B major 104.46±59.41 52.48±36.43 27.22±10.17 16.22±5.91 
HCV-G1b, IL28B major 93.30±36.74 43.52±20.99 24.65±7.37 16.82±6.20 
HCV-G1b, IL28B minor 92.92±42.21 41.53±20.32 22.10±6.69* 19.14±8.25 
(mg/dl) 
*P>0.05 vs HCV-G2, **P>0.05 vs HCV-G1b with IL28B major, ***P>0.01 vs HCV-G1b with IL28B major 
Table 1. Differences in lipoprotein fractions among patients with chronic HCV-G1b and G2 infection 
with different IL28 genotype 
In patients with HCV-G1b having the IL28B major (responder) genotype, the concentration 
of cholesterol in the LDL fraction (LDL-C) was significantly lower than that in patients with 
HCV-G2. In addition, the tendency of a reciprocal increase of VLDL-C (P=0.055) in HCV-
G1b patients having the responder genotype was observed. As a result, the level of LDL-C 
plus VLDL-C was similar between these two groups. In contrast, a reciprocal increase of 
VLDL-C was not observed in G1b patients who had the non-responder genotype. Decrease 
of VLDL-C and increase of HDL-C is a feature of the non-responder genotype compared 
with the responder genotype in chronic HCV-G1b patients. 
We also examined serum lipoprotein profiles of five patients who had been infected with 
HCV-G1b, but achieved SVR by PEG-IFN plus RBV therapy (HCV-free status continuing for 
longer than 6 months). In these cured patients, low levels of VLDL-C and high levels of 
LDL-C and HDL-C were observed (Table 2). The lipoprotein profiles of these cured patients 
were quite normal with a normal composition of cholesterol and TG in each lipoprotein 
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fraction when assessed by C:T ratio. When compared with cured patients, a relative 
decrease of TG in the VLDL fraction and a relative increase of TG in the LDL and HDL 
fractions were noted in chronic HCV infection. 
In chronic HCV infection, we unexpectedly found that the serum levels of LDL-C measured 
by an HPLC system (LipoSEARCH) were considerably lower than those measured directly 
using a conventional method (HCV-G1b: 93.8±26.76 mg/dl; HCV-G2: 101.21±34.19 mg/dl), or 
measured indirectly by the Friedwald equation. In place of the decreased LDL fraction, the 
VLDL fraction was increased. This pattern is somewhat reminiscent of hyperlipidemic (high 
TG) samples [31]. However, in chronic HCV infection, TG levels are not much different from 
those in cured patients. Therefore, this finding cannot be explained by an increase of TG.  
 
Lipoprotein fraction TC VLDL-C LDL-C HDL-C 
HCV-G1b, achieved 
SVR   
177.49±35.63 26.34±7.24 89.41±31.61 61.28±15.14 
(mg/dl) 
 TG VLDL-TG LDL-TG HDL-TG 
HCV-G1b, achieved 
SVR 
79.15±25.33 44.11±18.77 22.08±4.96 10.47±2.64 
(mg/dl) 
Table 2. Serum lipid profiles of patients who achieved SVR by PEG-IFN plus RBV therapy for chronic 
HCV-G1b infection (sera were obtained at least 6 months after HCV was completely eradicated) 
An increase of the VLDL fraction in chronic HCV infection could be explained by reduced 
enzymatic activity of lipoprotein lipase, which may facilitate HCV cell entry [23] while 
delaying the conversion of VLDL to LDL. Alternatively, discrepancy between chemically 
determined LDL (conventional measurement method) and levels determined by particle 
size (HPLC-based method) may be explained by the existence of LDL-associated LVPs in the 
blood during chronic HCV infection. These particles may have the physicochemical surface 
nature of LDLs, but particle sizes larger than 55 nm because the diameter of the HCV 
particle is about 55 nm, and hence must be eluted in the VLDL fraction. Although we must 
take into consideration that lipoprotein particles could theoretically become fused together 
during freezing and thawing, thus seriously distorting the lipoprotein fraction pattern 
determined by the HPLC-based method, freezing and thawing has reportedly been found 
not to seriously affect lipoprotein profiles (Skylight Biotech, http://www.lipo-search.com). 
A recent study by Nishimura et al. [37] suggested that diminished VLDL-TG/non-VLDL-TG 
is a key feature of chronic HCV infection. They detected VLDL-TG based on the chemical 
nature of VLDL. Their findings do not conflict with our data. Our results indicate a relative 
decrease of TG in the VLDL fraction, but a relative increase of TG in the LDL and HDL 
fractions. Thus, their findings of decreased VLDL-TG/non-VLDL-TG appear to be consistent 
with our results. 
As this kind of lipid abnormality is not easily determined by conventional methodology, the 
HPLC-based method is extraordinarily useful for the study of lipoprotein profiles in chronic 
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HCV infection. However, close attention to sample handling is needed because lipoprotein 
particles are fairly unstable. 
The tentative conclusions are as follows: 1. Decrease of apoB (apoB-100) and apoB-100-
related cholesterol might be a main feature of dyslipoproteinemia in chronic HCV-G1b 
infection with unfavorable response to PEG-IFN plus RBV combination therapy; 2. Existence 
of abnormally large particles (LPVs) eluted in the VLDL fraction by HPLC, in spite of the 
chemical characteristics of LDL, and/or reduced activity of lipoprotein lipase with delayed 
VLDL dissociation, may be a feature of dyslipoproteinemia in chronic HCV infection; 3. 
Relative increase of TG in the LDL and HDL fractions with a relative decrease of TG in the 
VLDL fraction may be a feature of chronic HCV infection. These conclusions are partially in 
concordance with those reported by Mawatari et al. [38]. 
4. Do viral factors participate in the dyslipoproteinemia seen during 
chronic HCV-G1b infection? 
HCV-G1 infection is widely distributed worldwide and the most common genotype in the 
world, while it is one of the most resistant genotypes to IFN-based therapy. In Japan, almost 
all G1 subtypes are 1b, contributing to more than 70% of chronic HCV infection cases. Viral 
factors participating in the response to IFN-based therapies have been extensively studied, 
especially with regard to HCV-G1b in Japan. Among them, core protein substitution at aa 
70/91 [32] and aa substitutions in the ISDR [33], IRRDR [34] and in NS5A are widely 
accepted as candidates. Among them, substitution at core protein 91, Leu91Met, did not 
affect serum levels of apoB-100 as reported earlier by us [36]. We further examined the 
significance of substitution at aa 70, Arg70Gln/His, aa substitutions in the ISDR and IRRDR 
and aa substitutions at particular positions within the IRRDR. 
In that former study, we determined that substitution of Arg70 to Gln/His70 was a 
distinctive factor participating in the regulation of serum apoB-100 levels in chronic HCV-
G1b patients, independent from the IL28B genotype. To clarify the lipoprotein profiles 
according to substitution at aa 70, we examined the lipoprotein profiles of fasting sera from 
113 chronic HCV-G1b patients (68 were Arg70 and 45 were Gln/His70) by LipoSEARCH, as 
described earlier (Table 3). 
 
Lipoprotein fraction TC VLDL-C LDL-C HDL-C 
HCV-G1b    Arg70 169.80±30.75 43.16±18.39 74.23±18.68 48.09±14.03 
HCV-G1b  Gln/His70 158.54±28.44 40.02±17.40 65.99±15.51* 47.57±14.09 
(mg/dl) 
Lipoprotein fraction TG VLDL-TG LDL-TG HDL-TG 
HCV-G1b    Arg70 89.49±33.68 42.15±20.80 23.53±6.71 16.24±5.31 
HCV-G1b  Gln/His70 95.95±41.99 42.13±19.50 18.14±7.83 19.42±8.31* 
(mg/dl) 
(*: p>0.05) 
Table 3. Differences in lipoprotein profiles related to the substitution at aa 70 in core region (Arg70 to 
Gln/His70) in patients with chronic HCV-G1b infection 
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There were no differences related to gender, age, fibrosis score of liver biopsy, BMI, serum 
ALT level, viral load or platelet count between Arg70 and Gln/His70. However, a significant 
difference was found in the distribution of the IL28B genotype (SNP of rs8099917). In Arg70, 
49 patients were of the major (responder) genotype while 15 were of the minor (non-
responder) genotype. In Gln/His70, 22 were major and 20 were minor. A total of 7 patients 
remained undetermined. The difference in the IL28B genotype distribution between these 
two groups was significant (P=0.0005 by chi-square test with Yate’s correction). Therefore, 
the influence of the IL28B genotype was not excluded in this study. However, the pattern of 
dyslipoproteinemia seen in Gln/His70 cases is dissimilar to that in the IL28B minor 
genotype, which was described in detail. In core 70 mutants (Gln/His70), a significant 
decrease in LDL-C and increase in HDL-TG levels was demonstrated without a decrease in 
VLDL-C. TC levels tended to be lower than that in the core Arg70 cases (P=0.052). These 
findings may indicate that the core mutation at aa 70 is an important viral feature in relation 
to the dyslipoproteinemia seen in HCV-G1b, functioning mainly through decreasing LDL-C. 
As a result of the substitution at aa 70, the nature of the amino acid is substantially changed. 
Therefore, the configuration and the biological activity of the core protein may be 
significantly disturbed, which may lead to the disruption of lipid metabolism. However, the 
precise mechanism of the consequence of aa 70 substitution on lipid metabolism is a matter 
to be solved in the future. 
To exclude the influence of the IL28B genotype, we further compared the lipoprotein 
profiles in 49 patients with core 70 wild-type, and 22 patients with core 70 mutant 
phenotypes in whom the IL28B genotype was major (Table 4). 
 
Lipoprotein fraction TC VLDL-C LDL-C HDL-C 
HCV-G1b    Arg70 173.37±30.83 45.80±18.29 76.41±18.28 46.38±12.37 
HCV-G1b  Gln/His70 155.44±24.13* 41.01±17.02 65.71±13.34* 45.72±12.45 
(mg/dl) 
Lipoprotein fraction TG VLDL-TG LDL-TG HDL-TG 
HCV-G1b    Arg70 92.33±35.95 42.57±22.27 25.50±6.77 15.87±5.28 
HCV-G1b  Gln/His70 93.44±36.33 41.36±17.84 26.12±8.72 18.28±7.38 
(mg/dl) 
(*: p>0.05) 
Table 4. Differences in lipoprotein profiles related to substitution at aa 70 in the core region (Arg70 to 
Glun/His70) in patients with chronic HCV-G1b having IL28B major (responder) genotype 
Although a relatively small-sized study, the features of the dyslipoproteinemia seen in 
patients with the core aa 70 mutation was clearly elucidated as a decrease of TC due to a 
decrease of LDL-C. Even after exclusion of the influence of the IL28B genotype, the core 70 
aa substitution was found to have a role in dyslipoproteinemia that may be critical. 
We also examined aa substitutions in the NS5A region in relation to disturbance of serum 
lipid/lipoprotein levels, since NS protein may inhibit the secretion of apoB-100 in vitro [12]. 
Moreover, a polypeptide comprised of aa residues 2135 to 2419 within the NA5A protein co-
precipitated with apoB, suggesting a possible interaction between NS5A protein and apoB-
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100. Thus, we examined aa substitutions in particular regions of NS5A to elucidate the 
possibility of a viral factor being the determinant of lipid metabolism. We compared the aa 
sequence 2209-2248 (ISDR) with the sequence of HCV-J and the number of aa substitutions 
was classified as wild-type (0 or 1) or non-wild-type (≥2). According to the numbers of aa 
substitutions in the ISDR [33], 102 of 117 subjects were judged to be wild-type and 15 non-
wild-type. No significant differences in serum apoB and lipid concentrations were found 
between wild-type and non-wild-type ISDR (Table 5).  
 
Lipid profile T.C. TG LDL-C* apoB 
ISDR      wild 172.8±32.0 104.3±54.1 92.5±26.6 80.9±19.8 
ISDR  non-wild 167.1±28.0 82.2±26.2 92..9±22.1 78.2±13.9 
(mg/dl) 
*measured directly using commercial kit. Note the substantial differences of LDL-C level measured by 
HPLC system shown in Table 1, Table 2 and Table 3.
Table 5. Lipid profiles of HCV-G1b patients with ISDR wild and ISDR non-wild 
Although not described in Table 5, there was no statistical difference between patients with 
wild-type and non-wild-type ISDR in terms of serum levels of apoAI, apoAII, apoCII, apoCIII, 
apoE and apoB-48. We also compared lipid profiles between patients with a substitution 
number of 0 (N=80) and ≥1 (N=37), and found no significant difference (data not shown). 
We very recently examined the aa substitution number and the place of substitution in the 
IRRDR (aa 2334-2376) in 105 patients who were chronically infected with HCV-G1b. By 
comparison with the HCV-J sequence, the number of aa substitutions was determined. A 
high degree (≥6 substitutions) of sequence variation in the IRRDR, which is thought to be a 
useful marker for predicting SVR [34], was found in 34 patients, whereas a less diverse (≤5 
substitutions) IRRDR sequence (predictive of non-SVR) was found in 71 patients. 
The clinical background is illustrated in Table 6. 
 
Gender (M/F) 42/63 TG 89.8±40.2 (mg/dl) 
Age  62.9±12.0 (years) LDL-C  95.5±29.2 (mg/dl) 
ALT 53.5±38.5 (U/L) apoB-100 73.0±21.1 (mg/dl) 
Albumin 4.1±0.4 (g/dl) rs8099917 (Major/Minor) 65/40 
Plt 16.0±6.3x104 aa 70 (Wild/Mutant) 64/41 
HCV-RNA  6.4±0.6 (logIU/ml)  aa 91 (Wild/Mutant) 63/42 
TC 171.3±32.7 (mg/dl) ISDR (Wild / Mutant) 92/12 
Table 6. Clinical characteristics of 105 HCV-G1b patients whose IRRDR sequences were examined 
The number of aa substitution detected in this study was illustrated in Figure 3. 
As shown in Figure 3, the substitution number in the IRRDR was widely distributed. There 
was no difference in lipid profile between the two groups (substitution number ≥6 vs. 
substitution number ≤5) along with other clinical backgrounds except for the distribution of 
the IL28B genotype (Table 7). 
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Figure 3. Distribution of aa substitution number in the IRRDR among 105 chronic HCV-G1b patients 
 
 Substitutions (≤5) Substitutions (≥6) P value
TC 171 (115-253) 160 (96-268) 0.10
TG 81(42-267) 82 (37-207) 0.83
LDL-C 93 (36-193) 86 (50-172) 0.40 
apoB-100  75 (39-131) 72 (44-135) 0. 23
IL28-B (TT/nonTT) 39/35 20/5 0.024
Data were expressed as median (range)
Table 7. Differences in lipid profile according to the substitution number in the IRRDR 
Next, we examined the relationship between each aa substitution in the IRRDR and 
dyslipoproteinemia. As illustrated in Figure 4, substitution at aa 2356 may impact serum lipid 
profiles. There was no difference in lipid profile related to substitutions other than aa 2356.  
A substitution at aa 2356 from Gly to Glu, Lys or Ala may be critical for distortion of the 
serum lipid profile. This substitution was previously shown to be a key substitution 
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determining virological outcome of PEG-IFN plus RBV therapy in HCV-G1b patients [39]. 
The therapeutic outcome of 63 patients treated with PEG-IFN plus RBV is indicated in the 
lower right of Figure 4. Although a clear difference was not observed in the outcome of the 
therapy, NVR tended to be frequent in patients with non-Gly at aa 2356. The substitution at 
aa 2356 of Gly to Glu or Gly to Lys caused a drastic change in the nature of the amino acid 
that may influence the nature of the protein and in turn affect the biochemical interaction of 
apoE or apoB-100 with NA5A protein resulting in the decrease of serum apoB-100 and LDL-
C. However, the change in serum apoB-100 level was minor. As aa substitution in the 
IRRDR is somewhat related to aa substitution in other regions such as the core aa 70, further 
examination is needed to establish the importance of aa 2356 substitution on lipoprotein 
metabolism in chronic HCV-G1b infection. 
 
Figure 4. Consequence of substitution at aa 2356 from G to E, K or A in the IRRDR. Serum levels of TC, 
LDL-C and apoB-100 were significantly higher in patients who had G2356 than in patients who had not. 
At lower right, the virological response to PEG-IFN plus RBV therapy in 63 patients with HCV-G1b was 
summarized.  
5. Are lipid/lipoprotein profiles independent predictors of therapeutic 
outcome in chronic HCV- G1b infection? 
Chronic HCV infection has been treated with PEG-IFN and RBV combination therapy. 
HCV-G2 and HCV-G3 responded fairly well to this combination therapy. However, the 
response was weaker in HCV-G1 patients with only half of the patients achieving a 
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sustained virological response. Before the discovery of the IL28B genotype, a decrease in TC, 
LDL-cholesterol or apoB-100-related cholesterol had been considered as an independent 
predictor of the outcome of PEG-IFN plus RBV therapy in HCV-G1. However, after the 
discovery that the genotype near the IL28B gene was a potent predictor, serum lipid levels 
have since been considered to be a confounding factor of the IL28B genotype. Actually, as 
we described earlier in this chapter and also in an earlier manuscript [36], the IL28B 
genotype may profoundly affect serum lipid levels in HCV-G1b infection. 
Our latest knowledge, based on a prospective study examining predictive factors for the 
outcome of PEG-IFN plus RBV therapy, indicates that an increase in serum apoB-100 levels is 
an independent factor predicting rapid virological response (decline of serum HCV RNA at 4 
weeks) to PEG-IFN plus RBV therapy. However, it does not appear to be an independent 
predictor of the final outcome of virological response in chronic HCV-G1b infection (data 
currently under consideration for contribution). These findings may partly indicate that 
disturbance of the lipid profile may reflect the efficiency of HCV replication due to efficient 
entry of HCV into hepatic cells and efficient production/secretion of HCV along with VLDL. 
Although the evidence described in this chapter is not based on in vitro studies using HCV-
secreting cells, our observations based on clinical samples may contribute to furthering the 
understanding of HCV-lipid metabolism interaction. From this viewpoint, it is noteworthy 
that lipoprotein lipase may act not only in the conversion of VLDL to LDL, but also in 
inhibiting HCV entry into liver cells [23]. Interestingly, in in vitro studies using naturally 
HCV-secreting cells, the enzymatic activity of lipoprotein lipase may be reduced in HCV-
infected cells and may act to promote cell entry of HCV. This may contribute to an increase 
in the number of large-size (suitable for VLDL particle size) LVP having a chemical nature 
of LDL as suggested in our HPLC-based study. 
Finally, hepatic steatosis may be associated with dyslipoproteinemia in chronic HCV 
infection and has been extensively studied with special attention to its relation to the IL28B 
genotype [40] and substitution at aa 70 [17] in HCV-G1b. However, in our experience, the 
relationship between hepatic steatosis and these host and/or viral factors was equivocal, 
perhaps because there are other environmental and host factors strongly affecting hepatic 
steatosis other than the factors discussed in this manuscript. 
6. Summary 
The features of dyslipoproteinemia in chronic HCV infection have been described. Serum 
lipid/lipoprotein profiles were in part HCV-genotype specific. The HCV core protein of HCV-
G1b is closely associated with lipoprotein metabolism, and substitution of amino acid (aa 70) 
in the core protein may precipitate dyslipoproteinemia, in addition to substitution of aa 2356 in 
NS5A. In addition, dyslipoproteinemia in chronic HCV-G1b infection is largely affected by the 
genotype near the human IL28B gene. Therefore, dyslipoproteinemia in chronic HCV infection 
may involve complicated interplay between viral and host factors that could affect human 
lipid metabolism. Further study of lipids/lipoproteins in chronic HCV infection will be 
valuable to clarify the interaction of HCV and host lipid metabolism in detail. 
Dyslipoproteinemia in chronic HCV-G1b infection may play a role in the rapid decline of HCV 
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during PEG-IFN plus RBV therapy. However, the clinical utility of dyslipoproteinemia as a 
predictor of final response to PEG-IFN plus RBV treatment remains controversial. 
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